Aradigm Corp. (ARDM) Announces Mixed Results from Two Pulmaquin Phase 3s in non-CF BE; ORBIT-3 Missed Endpoints

December 1, 2016 7:06 AM EST Send to a Friend
Aradigm Corporation (Nasdaq: ARDM) announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login